Few data exist on differences in gut microbiota composition among principal gastrointestinal (GI) diseases. We evaluated the differences in gut microbiota composition among uncomplicated diverticular disease (DD), irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD) patients. DD, IBS, and IBD patients along with healthy controls (CT) were enrolled in our Italian GI outpatient clinic. Stool samples were collected. Microbiota composition was evaluated through a metagenomic gene-targeted approach. GI pathology represented a continuous spectrum of diseases where IBD displayed one extreme, while CT displayed the other. Among Phyla, Biplot PC2/PC3 and dendogram plot showed major differences in samples from IBS and IBD. DD resembled species CT composition, but not for Bacteroides fragilis. In IBS, Dialister spp. and then Faecalibacterium prausnitzii were the most representative species. Ulcerative colitis showed a reduced concentration of Clostridium difficile and an increase of Bacteroides fragilis. In Crohn's disease, Parabacteroides distasonis was the most represented, while Faecalibacterium prausnitzii and Bacteroides fragilis were significantly reduced. Each disorder has its definite overall microbial signature, which produces a clear differentiation from the others. On the other hand, shared alterations constitute the “core dysbiosis” of GI diseases. The assessment of these microbial markers represents a parameter that may complete the diagnostic assessment.

Keywords:
Gut Microbiota, Crohn’s disease, Ulcerative colitis, Irritable bowel syndrome, Diverticular disease
1.
Scaldaferri F, et al: The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012;46(suppl):S12-S17.
2.
Walker WA, et al: Intestinal uptake of macromolecules. III. Studies on the mechanism by which immunization interferes with antigen uptake. J Immunol 1975;115:854-861.
3.
Walker WA, et al: Intestinal uptake of macromolecules. IV.-The effect of pancreatic duct ligation on the breakdown of antigen and antigen-antibody complexes on the intestinal surface. Gastroenterology 1975;69:1223-1229.
4.
Leser TD, Molbak L: Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol 2009;11:2194-2206.
5.
Neish AS: Microbes in gastrointestinal health and disease. Gastroenterology 2009;136:65-80.
6.
Eckburg PB, et al: Diversity of the human intestinal microbial flora. Science 2005;308:1635-1638.
7.
Gill SR, et al: Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-1359.
8.
Scanlan PD, Marchesi JR: Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces. ISME J 2008;2:1183-1193.
9.
Backhed F, et al: Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920.
10.
McCracken VJ, Lorenz RG: The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001;3:1-11.
11.
Lievin-Le Moal V, Servin AL: The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006;19:315-337.
12.
Manson JM, Rauch M, Gilmore MS: The commensal microbiology of the gastrointestinal tract. Adv Exp Med Biol 2008;635:15-28.
13.
Parashar UD, et al: Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304-306.
14.
Daniels L, Philipszoon LE, Boermeester MA: A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. Dis Colon Rectum 2014;57:539-543.
15.
Chang C, Lin H: Dysbiosis in gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2016;30:3-15.
16.
Choung RS, Locke GR 3rd: Epidemiology of IBS. Gastroenterol Clin North Am 2011;40:1-10.
17.
Mayer EA, Savidge T, Shulman RJ: Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014;146:1500-1512.
18.
Strate LL, et al: Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012;107:1486-1493.
19.
Cenit MC, et al: Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim Biophys Acta 2014;1842:1981-1992.
20.
Hold GL, et al: Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol Ecol 2002;39:33-39.
21.
Ley RE, et al: Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102:11070-11075.
22.
Ley RE, Peterson DA, Gordon JI: Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006;124:837-848.
23.
Frank DN, et al: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007;104:13780-13785.
24.
Rajilic-Stojanovic M, Smidt H, de Vos WM: Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007;9:2125-2136.
25.
Tap J, et al: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009;11:2574-2584.
26.
Lepage P, et al: Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011;141:227-236.
27.
Gevers D, et al: The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15:382-392.
28.
Martinez-Medina M, et al: Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009;15:872-882.
29.
Berry D, Reinisch W: Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol 2013;27:47-58.
30.
Lopetuso LR, et al: Gut microbiota: a key modulator of intestinal healing in inflammatory bowel disease. Dig Dis 2016;34:202-209.
31.
Sokol H, et al: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-16736.
32.
Lopetuso LR, et al: Gut virome and inflammatory bowel disease. Inflamm Bowel Dis 2016;22:1708-1712.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.